Peijia Medical (HKG:9996)'s registration application for the TaurusTrio Transcatheter Aortic Valve (TAV) system has been accepted by China's National Medical Products Administration, a Monday filing with the Hong Kong bourse said.
The TaurusTrio TAV system, which is developed and manufactured by the company based on the exclusive license obtained from JenaValve Technology, is designed to treat patients with native symptomatic severe aortic regurgitation through transfemoral access.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.